Ozempic vs Retatrutide: What to Know
Retatrutide is a new medication in development from Eli Lilly. It uses three hormones — a completely different approach from Ozempic's single-hormone design.
Helpful Products for GLP-1 Treatment
Managing your GLP-1 medication is easier with the right tools:
- Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
- Ginger products — Manage nausea with ginger chews or ginger tea.
- Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
- Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.
Quick Comparison
| Ozempic | Retatrutide | |
|---|---|---|
| Active drug | Semaglutide | Retatrutide |
| Drug class | GLP-1 agonist | Triple GIP/GLP-1/Glucagon agonist |
| FDA approval | Type 2 diabetes (approved) | Phase 3 trials (positive results as of May 2026) |
| Dosing | Once weekly | Once weekly (in trials) |
| Maker | Novo Nordisk | Eli Lilly |
| Status | Available now | Phase 3 complete (not yet FDA-approved) |
How They Work
Ozempic mimics one hormone (GLP-1) that signals fullness and slows digestion.
Retatrutide mimics three hormones:
- GLP-1 — signals fullness
- GIP — boosts the GLP-1 effect
- Glucagon — increases calorie burning
Three signals instead of one. That's the big difference.
Weight Loss Results
From clinical trials (as of May 2026):
- Ozempic: ~10-15% body weight loss
- Retatrutide (Phase 3): up to 28.7% body weight loss at 12 mg dose (TRIUMPH-4, 68 weeks)
- Retatrutide (Phase 3): up to 16.8% body weight loss in type 2 diabetes (TRANSCEND-T2D-1, 40 weeks)
Retatrutide has shown much stronger weight loss in Phase 3 trials — up to 28.7% vs around 10-15% for Ozempic. But these are different drugs from different companies at different stages of development.
Side Effects
Ozempic side effects:
- Nausea (most common)
- Diarrhea or constipation
- Dysesthesia (tingling or burning sensation) — more common at higher doses
- Decreased appetite
- Stomach pain
Retatrutide side effects (from trials):
- Nausea
- Decreased appetite
- Increased heart rate (from glucagon)
- Diarrhea or constipation
- Dysesthesia (tingling or burning sensation) — more common at higher doses
The glucagon component in Retatrutide may cause a slightly higher heart rate, which is being monitored.
Availability
Retatrutide is not yet FDA-approved. Two Phase 3 trials have reported positive results. Seven more Phase 3 readouts are expected in 2026. The earliest likely FDA filing is late 2026 or 2027, with potential approval in 2027.
Cost
No pricing yet for Retatrutide. Likely similar to other Eli Lilly GLP-1 medications (~$1,060/month).
Who Might Benefit from Retatrutide?
- People who don't get enough weight loss from semaglutide
- People who want the strongest possible results
- People open to trying a new class of medication
FAQ
When will retatrutide be approved by the FDA?
Retatrutide is not yet FDA-approved. As of May 2026, two Phase 3 trials have reported positive results, with seven more Phase 3 readouts expected in 2026. The earliest likely FDA filing is late 2026 or 2027, with potential approval in 2027.
Is retatrutide better than Ozempic for weight loss?
Phase 3 trial data shows retatrutide produced up to 28.7% body weight loss compared to approximately 10-15% for Ozempic. Early data suggests a significant advantage, but retatrutide is not yet approved and direct head-to-head comparisons are limited.
Why does retatrutide cause increased heart rate?
Retatrutide includes a glucagon receptor agonist component. Glucagon increases metabolic rate and energy expenditure, which can also raise heart rate slightly. This side effect is being monitored closely in ongoing Phase 3 trials.
Should I wait for retatrutide instead of starting Ozempic?
No. Retatrutide will not be available until at least 2027. If you need weight management help now, Ozempic and other approved GLP-1 medications are available and effective. Talk to your doctor about the best current option for you.
Bottom Line
Ozempic is available now and works well for millions of people. Retatrutide offers much stronger weight loss in Phase 3 trials (up to 28.7% vs 10-15%), but it is not yet FDA-approved. The earliest possible approval is likely 2027. If Ozempic is working for you, there's no reason to wait. If you're not getting the results you want, talk to your doctor about current options like tirzepatide (Mounjaro/Zepbound).
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary.